Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie IncfiledCriticalAbbvie Inc
Priority to MYPI99002107ApriorityCriticalpatent/MY116032A/en
Publication of MY116032ApublicationCriticalpatent/MY116032A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A LIQUID PHARMACEUTICAL COMPOSITION PROVIDING IMPROVED ORAL BIOAVAILABILITY IS DISCLOSED FOR COMPOUNDS WHICH ARE INHIBITORS OF HIV PROTEASE.IN PARTICULAR, THE COMPOSITION COMPRISES A SOLUTION IN A PHARMACEUTICALLY ACCEPTABLE ORGANIC SOLVENT OF (A) THE HIV PROTEASE INHIBITOR AND, OPTIONALLY, (B) A SURFACTANT. THE COMPOSITION CAN OPTIONALLY BE ENCAPSULATED IN EITHER HARD GELATIN CAPSULES OR SOFT ELASTIC CAPSULES (SEC).
MYPI99002107A1999-05-271999-05-27Liquid composition comprising an hiv protease inhibitor and a, c12-c18 fatty acid
MY116032A
(en)
SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
Liquid immediate release pharmaceutical formulation comprising an acid addition salt of a substituted azetidine derivative compound and a pharmaceutically acceptable diluent or carrier useful for the treatment or prevention of thrombosis.
"soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."